An investigation for investors in NASDAQ:ZIOP shares over potential securities laws violations by ZIOPHARM Oncology was announced and NASDAQ:ZIOP stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 07/26/2016 -- An investigation on behalf of investors of ZIOPHARM Oncology Inc. shares over potential securities laws violations by ZIOPHARM Oncology and certain of its directors was announced.
Investors who purchased shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm focuses on whether a series of statements by ZIOPHARM Oncology regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On July 14, 2016, ZIOPHARM Oncology Inc revealed that a brain cancer patient in an ongoing clinical trial had died after being treated with Ad-RTS-hIL-12, the Company's experimental gene therapy. A Ziopharm spokesman commented that ZIOPHARM Oncology Inc had not yet informed the U.S. Food and Drug Administration of the death. ZIOPHARM Oncology Inc then disclosed a second death of a patient in clinical study, but said the death was unrelated to Ad-RTS-hIL-12. Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) declined to as low as $4.46 per share on July 19, 2016.
On July 25, 2016, NASDAQ:ZIOP shares closed at $4.66 Per share.
Those who purchased shares of ZIOPHARM Oncology Inc. have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com